SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERAPRNewsWire • 02/07/23
Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockGlobeNewsWire • 02/02/23
Vera Therapeutics Announces Commencement of Public Offering of Class A Common StockGlobeNewsWire • 02/01/23
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in ProteinuriaGlobeNewsWire • 01/30/23
5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)Benzinga • 01/13/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 01/12/23
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)Benzinga • 01/10/23
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook PoppedInvestors Business Daily • 01/04/23
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyGlobeNewsWire • 01/03/23
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/20/22
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCPGlobeNewsWire • 11/17/22
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/09/22
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney WGlobeNewsWire • 11/05/22
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202GlobeNewsWire • 10/17/22
Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a BetZacks Investment Research • 09/15/22
Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High?Zacks Investment Research • 08/29/22
Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/12/22
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/10/22
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/04/22